Aktien Sensor

DSM-Firmenich solidifies its industry leadership through strategic investments and partnerships, including a new plant-derived exosome investment and the launch of a precision-fermented dairy protein ingredient.

DSM-Firmenich reports strong financial performance and ambitious sustainability goals, with plans for a €1 billion share buyback and a €2.4 billion adjusted EBITDA target for 2025.

DSM-Firmenich’s 2024 financials show a remarkable turnaround, with all businesses performing exceptionally well and a significant increase in organic sales growth, driven by the company’s bold strategic plan focusing on innovation and consumer-centricity.